查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954333

疫苗市场分析及预测（至2035年）：类型、产品、技术、应用、最终使用者、流程、给药方式、材料类型及设备

Vaccines Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Deployment, Material Type, Device
出版日期: | 出版商: Global Insight Services | 英文 349 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计疫苗市场规模将从2024年的671亿美元成长到2034年的1,380亿美元，年复合成长率约为8.1%。疫苗市场涵盖生物製药的研发、生产和分销，这些生物製品能够提供针对感染疾病的免疫力。这包括针对病毒、细菌和其他病原体的各种疫苗。推动该市场成长的因素包括生物技术的进步、感染疾病率的上升以及政府推广疫苗接种的措施。疫苗递送系统的创新，例如mRNA技术和无针注射，对于应对全球健康挑战和拓展市场机会至关重要。

疫苗市场正经历强劲成长，这主要得益于生物技术的进步和人们健康意识提升的提高。感染疾病疫苗是推动市场成长的主要动力，其中流感疫苗和肺炎链球菌感染疫苗表现特别出色。这些疫苗对于减轻疾病负担和降低医疗成本至关重要。癌症疫苗紧随其后，这得归功于免疫疗法和个人化医疗的创新。针对特定癌症类型的治疗性疫苗因其改善患者预后的潜力而备受关注。儿童疫苗市场也展现出巨大的潜力，针对麻疹和脊髓灰质炎等疾病的常规免疫接种需求依然强劲。联合疫苗因其便利性和免疫抗原性，正逐渐成为首选。成人疫苗市场也持续扩张，重点在于增强对带状疱疹和肝炎等疾病的免疫力。持续的研发投入和策略合作对于维持市场成长和满足未被满足的需求至关重要。

市场区隔
种类 减毒活病毒疫苗、灭活疫苗、次单位疫苗、类毒素疫苗、结合疫苗、DNA疫苗、重组载体疫苗
产品 人用疫苗、兽用疫苗、儿童疫苗、成人疫苗、旅游疫苗
科技 重组技术、细胞培养技术、基因编辑技术、奈米颗粒技术
适用的 感染疾病、癌症、过敏、神经系统疾病
最终用户 医院、诊所、研究机构、製药公司、生技公司、政府机构
过程 研发、製造和分销
实施表格 本机部署、云端部署
材料类型 生物来源，合成
装置 注射器，无针注射器

疫苗市场竞争激烈，各公司透过价格战和创新产品推出争夺市场份额。这种动态格局受到新疫苗不断涌现的影响，这些新疫苗旨在应对新出现的健康威胁。各公司会根据市场状况调整价格，以便在保持盈利的同时提高疫苗的可及性。新配方和给药系统的持续研发体现了疫苗产业对创新和公共卫生的承诺。疫苗市场竞争异常激烈，主要企业力求透过研发实现差异化。监管具有显着影响，严格的指导方针会影响新产品核可的速度。产业领导者和新兴生物技术公司共同塑造了竞争格局，它们利用科学进步来获得竞争优势。北美和欧洲等地区的法规结构至关重要，它们塑造着市场动态并影响战略决策。监管与创新之间的相互作用对决定市场走向至关重要。

主要趋势和驱动因素：

由于全球健康意识的不断提高和应对疫情的紧迫性，疫苗市场正经历强劲成长。关键趋势包括快速反应能力强、疗效高的mRNA疫苗的加速研发。各国政府正大力投资疫苗研发和生产基础设施，以确保对新出现的健康威胁做出快速反应。推动因素包括感染疾病的日益普及和全球疫苗接种计划的扩大。公私合营正在促进创新并支持疫苗分发，尤其是在低收入地区。对个人化医疗的关注也有助于开发针对特定族群的疫苗并提高其疗效。此外，生物技术和基因组学的进步正在推动开发具有更高安全性的新一代疫苗。新兴市场疫苗接种率的提高带来了许多机会。专注于创新递送系统并扩大全球业务的公司将能够充分利用这些趋势。随着世界继续应对健康挑战，在科学突破和国际合作的支持下，疫苗市场预计将继续保持持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 减毒活病毒疫苗
    • 灭活疫苗
    • 次单位疫苗
    • 类毒素疫苗
    • 结合疫苗
    • DNA疫苗
    • 重组载体疫苗
  • 市场规模及预测：依产品划分
    • 人类疫苗
    • 兽用疫苗
    • 儿童疫苗
    • 成人疫苗
    • 旅行疫苗
  • 市场规模及预测：依技术划分
    • 重组技术
    • 细胞培养技术
    • 基因编辑技术
    • 奈米颗粒技术
  • 市场规模及预测：依应用领域划分
    • 感染疾病
    • 癌症
    • 过敏
    • 神经系统疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究所
    • 製药公司
    • 生技公司
    • 政府机构
  • 市场规模及预测：依製程划分
    • 研究与开发
    • 製造业
    • 分配
  • 市场规模及预测：依发展状况
    • 本地部署
    • 基于云端的
  • 市场规模及预测：依材料类型划分
    • 生物製药
    • 合成
  • 市场规模及预测：依设备划分
    • 注射器
    • 无针注射器

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Sinovac Biotech
  • Bharat Biotech
  • Cure Vac
  • Novavax
  • Valneva
  • Emergent Bio Solutions
  • VBI Vaccines
  • Dynavax Technologies
  • Inovio Pharmaceuticals
  • Geo Vax Labs
  • Moderna
  • Bio NTech
  • Sanofi Pasteur
  • Glaxo Smith Kline
  • Pfizer
  • Astra Zeneca
  • Johnson & Johnson
  • Merck & Co
  • CSL Limited
  • Seqirus

第九章：关于我们

简介目录
Product Code: GIS32548

Vaccines Market is anticipated to expand from $67.1 billion in 2024 to $138.0 billion by 2034, growing at a CAGR of approximately 8.1%. The Vaccines Market encompasses the development, production, and distribution of biological preparations that provide immunity against infectious diseases. It includes a diverse range of vaccines targeting viruses, bacteria, and other pathogens. The market is driven by advancements in biotechnology, rising incidence of infectious diseases, and government initiatives promoting immunization. Innovations in vaccine delivery systems, such as mRNA technology and needle-free administration, are pivotal in addressing global health challenges and expanding market opportunities.

The Vaccines Market is experiencing robust growth, propelled by advancements in biotechnology and increasing awareness of preventive healthcare. The infectious diseases segment leads the market, with vaccines for influenza and pneumococcal infections demonstrating top performance. These vaccines are critical in reducing disease burden and healthcare costs. The cancer vaccines sub-segment follows closely, driven by innovations in immunotherapy and personalized medicine. Therapeutic vaccines targeting specific cancer types are gaining momentum due to their potential to improve patient outcomes. The pediatric vaccines segment also shows significant promise, with routine immunizations for diseases like measles and polio maintaining high demand. Combination vaccines are emerging as a preferred choice, offering convenience and enhanced immunogenicity. The adult vaccines segment is expanding, with a focus on boosting immunity against diseases such as shingles and hepatitis. Continuous research and development, alongside strategic collaborations, are vital in sustaining market growth and addressing unmet medical needs.

Market Segmentation
TypeLive Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines
ProductHuman Vaccines, Animal Vaccines, Pediatric Vaccines, Adult Vaccines, Travel Vaccines
TechnologyRecombinant Technology, Cell Culture Technology, Gene Editing Technology, Nanoparticle Technology
ApplicationInfectious Diseases, Cancer, Allergies, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Government Organizations
ProcessResearch and Development, Manufacturing, Distribution
DeploymentOn-Premise, Cloud-Based
Material TypeBiological, Synthetic
DeviceSyringes, Needle-Free Injectors

The vaccines market is characterized by a diverse array of players, each vying for market share through competitive pricing strategies and innovative product launches. The dynamic landscape is influenced by the introduction of novel vaccines addressing emerging health threats. Companies are strategically adjusting pricing to enhance accessibility while maintaining profitability. The continuous development of new formulations and delivery systems underscores the industry's commitment to innovation and public health. Competition within the vaccines market is intense, with key players striving for differentiation through research and development. Regulatory influences are significant, with stringent guidelines impacting the pace of new product approvals. The competitive landscape is shaped by industry giants and emerging biotech firms, each leveraging scientific advancements to gain a competitive edge. Regulatory frameworks in regions such as North America and Europe are pivotal, shaping market dynamics and influencing strategic decisions. The interplay between regulation and innovation is crucial in determining market trajectories.

Geographical Overview:

The vaccines market is witnessing robust growth across diverse regions, each presenting unique opportunities. North America remains a dominant player, driven by advanced healthcare infrastructure and substantial public and private investments in vaccine development. The region's focus on innovation and rapid adoption of new technologies bolsters its market position. Europe follows closely, with strong government support for vaccination programs and a well-established pharmaceutical industry. The region's commitment to public health and research excellence further enhances its market dynamics. In Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and a growing population. Countries such as China and India emerge as key growth pockets, with significant investments in vaccine research and manufacturing capabilities. Latin America and the Middle East & Africa are emerging markets with considerable potential. In Latin America, rising healthcare awareness and government initiatives drive market growth, while in the Middle East & Africa, improving healthcare infrastructure and increased vaccination efforts present new opportunities.

The global vaccines market is increasingly influenced by tariff impositions and geopolitical tensions, particularly in East Asia. Japan and South Korea are navigating these challenges by enhancing domestic vaccine production capabilities and fostering regional collaborations. China, amid trade tensions, accelerates its vaccine R&D and manufacturing self-sufficiency, while Taiwan focuses on maintaining its strategic position in biotech innovation. The parent market is buoyant, driven by heightened demand for vaccines and technological advancements. By 2035, the market is projected to thrive on diversified supply chains and cross-border partnerships. Meanwhile, Middle East conflicts exacerbate global supply chain vulnerabilities and elevate energy costs, indirectly impacting production and distribution logistics. These dynamics necessitate strategic agility and robust risk management for sustained market growth.

Key Trends and Drivers:

The vaccines market is experiencing robust growth, propelled by heightened global health awareness and the urgent need for pandemic preparedness. Key trends include the accelerated development of mRNA vaccines, which offer rapid response capabilities and strong efficacy. Governments are investing heavily in vaccine research and manufacturing infrastructure, ensuring swift responses to emerging health threats. Drivers include the rising prevalence of infectious diseases and the expanding immunization programs worldwide. Public-private partnerships are fostering innovation and facilitating the distribution of vaccines, particularly in low-income regions. The emphasis on personalized medicine is also encouraging the development of vaccines tailored to specific populations, enhancing their effectiveness. Moreover, technological advancements in biotechnology and genomics are enabling the creation of next-generation vaccines with improved safety profiles. Opportunities abound in emerging markets where vaccination coverage is increasing. Companies focusing on innovative delivery systems and expanding their global footprint are well-positioned to capitalize on these trends. As the world continues to grapple with health challenges, the vaccines market is poised for sustained expansion, driven by scientific breakthroughs and international collaborations.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Material Type
  • 2.9 Key Market Highlights by Device

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Live Attenuated Vaccines
    • 4.1.2 Inactivated Vaccines
    • 4.1.3 Subunit Vaccines
    • 4.1.4 Toxoid Vaccines
    • 4.1.5 Conjugate Vaccines
    • 4.1.6 DNA Vaccines
    • 4.1.7 Recombinant Vector Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Human Vaccines
    • 4.2.2 Animal Vaccines
    • 4.2.3 Pediatric Vaccines
    • 4.2.4 Adult Vaccines
    • 4.2.5 Travel Vaccines
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant Technology
    • 4.3.2 Cell Culture Technology
    • 4.3.3 Gene Editing Technology
    • 4.3.4 Nanoparticle Technology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Infectious Diseases
    • 4.4.2 Cancer
    • 4.4.3 Allergies
    • 4.4.4 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Pharmaceutical Companies
    • 4.5.5 Biotechnology Companies
    • 4.5.6 Government Organizations
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Research and Development
    • 4.6.2 Manufacturing
    • 4.6.3 Distribution
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 On-Premise
    • 4.7.2 Cloud-Based
  • 4.8 Market Size & Forecast by Material Type (2020-2035)
    • 4.8.1 Biological
    • 4.8.2 Synthetic
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Syringes
    • 4.9.2 Needle-Free Injectors

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Deployment
      • 5.2.1.8 Material Type
      • 5.2.1.9 Device
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Deployment
      • 5.2.2.8 Material Type
      • 5.2.2.9 Device
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Deployment
      • 5.2.3.8 Material Type
      • 5.2.3.9 Device
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Deployment
      • 5.3.1.8 Material Type
      • 5.3.1.9 Device
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Deployment
      • 5.3.2.8 Material Type
      • 5.3.2.9 Device
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Deployment
      • 5.3.3.8 Material Type
      • 5.3.3.9 Device
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Deployment
      • 5.4.1.8 Material Type
      • 5.4.1.9 Device
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Deployment
      • 5.4.2.8 Material Type
      • 5.4.2.9 Device
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Deployment
      • 5.4.3.8 Material Type
      • 5.4.3.9 Device
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Deployment
      • 5.4.4.8 Material Type
      • 5.4.4.9 Device
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Deployment
      • 5.4.5.8 Material Type
      • 5.4.5.9 Device
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Deployment
      • 5.4.6.8 Material Type
      • 5.4.6.9 Device
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Deployment
      • 5.4.7.8 Material Type
      • 5.4.7.9 Device
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Deployment
      • 5.5.1.8 Material Type
      • 5.5.1.9 Device
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Deployment
      • 5.5.2.8 Material Type
      • 5.5.2.9 Device
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Deployment
      • 5.5.3.8 Material Type
      • 5.5.3.9 Device
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Deployment
      • 5.5.4.8 Material Type
      • 5.5.4.9 Device
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Deployment
      • 5.5.5.8 Material Type
      • 5.5.5.9 Device
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Deployment
      • 5.5.6.8 Material Type
      • 5.5.6.9 Device
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Deployment
      • 5.6.1.8 Material Type
      • 5.6.1.9 Device
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Deployment
      • 5.6.2.8 Material Type
      • 5.6.2.9 Device
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Deployment
      • 5.6.3.8 Material Type
      • 5.6.3.9 Device
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Deployment
      • 5.6.4.8 Material Type
      • 5.6.4.9 Device
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Deployment
      • 5.6.5.8 Material Type
      • 5.6.5.9 Device

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sinovac Biotech
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bharat Biotech
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cure Vac
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Novavax
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Valneva
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Emergent Bio Solutions
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 VBI Vaccines
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Dynavax Technologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Inovio Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Geo Vax Labs
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Moderna
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bio NTech
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Sanofi Pasteur
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Glaxo Smith Kline
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pfizer
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Astra Zeneca
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Johnson & Johnson
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Merck & Co
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 CSL Limited
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Seqirus
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us